BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 265] [Cited by in F6Publishing: 278] [Article Influence: 66.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhang H, Zou Y, Xue Q, Li M, Yang H, Cheng H, Gu Y, Shen C, Tian Q, Wang S. Elemene oral emulsion attenuates colitis in mice by altering gut microbiome and regulating amino acids metabolism. Microbial Pathogenesis 2022;173:105821. [DOI: 10.1016/j.micpath.2022.105821] [Reference Citation Analysis]
2 Hu Q, Wang H, Xu T. Predicting hepatotoxicity associated with low-dose methotrexate using machine learning.. [DOI: 10.21203/rs.3.rs-1753066/v2] [Reference Citation Analysis]
3 Zambrano-sánchez R, Alvarez-mena P, Hidalgo D, Liquitay CME, Franco JVA, Vernooij RWM, Simancas-racines D, Viteri-garcía A, Montesinos-guevara C. Quality assessment of Clinical Practice Guidelines (CPG) for the diagnosis and treatment of inflammatory bowel disease using the AGREE II instrument: a systematic review. BMC Gastroenterol 2022;22:447. [DOI: 10.1186/s12876-022-02539-9] [Reference Citation Analysis]
4 Shiga H, Takahashi T, Shiraki M, Kojima Y, Tsuji T, Takagi S, Hiramoto K, Yokoyama N, Sugimura M, Iwabuchi M, Endo K, Onodera M, Sato Y, Shimodaira Y, Nomura E, Kikuchi T, Chiba H, Oomori S, Kudo H, Kumada K, Nagaie S, Ogishima S, Nagami F, Shimoyama Y, Moroi R, Kuroha M, Kakuta Y, Ishige T, Kinouchi Y, Masamune A. Reduced antiviral seropositivity among patients with inflammatory bowel disease treated with immunosuppressive agents. Scand J Gastroenterol 2022;:1-8. [PMID: 36222610 DOI: 10.1080/00365521.2022.2132831] [Reference Citation Analysis]
5 Kuwahara R, Ikeuchi H, Horio Y, Minagawa T, Kusunoki K, Uchino M. Have advances in medical therapy for ulcerative colitis impacted surgical treatment? Annals of Gastroent Surgery. [DOI: 10.1002/ags3.12626] [Reference Citation Analysis]
6 Chiba M, Tsuji T, Masai R, Odashima M, Sageshima M. Infliximab and Plant-Based Diet as First-Line Therapy Followed by Corticosteroid Therapy for Severe Ulcerative Colitis: A Case Report. Gastrointestinal Disorders 2022;4:230-236. [DOI: 10.3390/gidisord4040022] [Reference Citation Analysis]
7 Greco S, Bonsi B, Fabbri N. Diet and nutrition against inflammatory bowel disease: Trick or treat(ment)? World J Exp Med 2022; 12(5): 104-107 [DOI: 10.5493/wjem.v12.i5.104] [Reference Citation Analysis]
8 Emile SH, Freund MR, Horesh N, Garoufalia Z, Gefen R, Silva-Alvarenga E, Wexner SD. Risk factors and predictors of 30-day complications and conversion to open surgery after repeat ileocolic resection of Crohn's disease. Surg Endosc 2022. [PMID: 36068385 DOI: 10.1007/s00464-022-09557-4] [Reference Citation Analysis]
9 Masuda M, Fukata N, Sano Y, Nishimon S, Aoi M, Tomiyama T, Fukui T, Omiya M, Okazaki K, Naganuma M. Analysis of the initial dose and reduction rate of corticosteroid for ulcerative colitis in clinical practice. JGH Open 2022;6:612-620. [DOI: 10.1002/jgh3.12796] [Reference Citation Analysis]
10 Grace A, Usman MA, Ochayi MO, Adams MD, Umar HD, Obalum CD, Akunna GG, Meraiyebu AB, Onwuchekwa C. Elucidating the Anti-Oxidant and Anti-Inflammatory Potentials of Triticum aestivum Against Ulcerative Colitis: an In Vivo and In Silico Study. Phytomedicine Plus 2022. [DOI: 10.1016/j.phyplu.2022.100350] [Reference Citation Analysis]
11 Omar TA, Sweed E, Sweed D, Eledel RH, Abou-elela DH, Hikal G. Mesenchymal Stem Cells for the Treatment of Acetic Acid-Induced Ulcerative Colitis in Rats. Open Access Maced J Med Sci 2022;10:1478-1486. [DOI: 10.3889/oamjms.2022.10686] [Reference Citation Analysis]
12 Matsuoka K, Fujii T, Okamoto R, Yamada A, Kunisaki R, Matsuura M, Watanabe K, Shiga H, Takatsu N, Bamba S, Mikami Y, Yamamoto T, Shimoyama T, Motoya S, Torisu T, Kobayashi T, Ohmiya N, Saruta M, Matsuda K, Matsumoto T, Nakase H, Maemoto A, Shinzaki S, Murata Y, Yoshigoe S, Sasaki A, Yajima T, Hisamatsu T. Characteristics of adult patients newly diagnosed with Crohn's disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn's disease in Japan (iCREST-CD). J Gastroenterol 2022. [PMID: 35930087 DOI: 10.1007/s00535-022-01907-2] [Reference Citation Analysis]
13 Zambrano-sánchez R, Alvarez-mena P, Hidalgo D, Liquitay CME, Franco J, Vernooij RW, Simancas-racines D, Viteri-garcía A, Montesinos-guevara C. Quality assessment of Clinical Practice Guidelines (CPG) for the diagnosis and treatment of Inflammatory Bowel Disease using the AGREE II instrument: A Systematic Review.. [DOI: 10.21203/rs.3.rs-1754875/v1] [Reference Citation Analysis]
14 Ito C, Odajima K, Niimura Y, Fujii M, Sone M, Asakawa S, Arai S, Yamazaki O, Tamura Y, Saito K, Tada Y, Yamamoto T, Kozuma K, Shibata S, Fujigaki Y. IgA vasculitis with transient glomerular hematuria, diarrhea, and pericarditis following COVID-19 mRNA vaccination in a young patient with possible pre-existing ulcerative colitis. CEN Case Rep 2022. [DOI: 10.1007/s13730-022-00727-w] [Reference Citation Analysis]
15 Hassan SWU, Alam SN, Syed NU, Ismail M. Campylobacter jejuni pancolitis complicated by toxic megacolon in an immunocompetent host. BMJ Case Rep 2022;15:e249801. [DOI: 10.1136/bcr-2022-249801] [Reference Citation Analysis]
16 Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T, Motoya S, Maemoto A, Fujiya M, Ashida T, Goto M, Matsumoto T, Suzuki Y, Hamahata Y, Nakagawa T, Kato N, Kato J, Endo Y, Suzuki R, Matsuda K, Ohmiya N, Katsushima S, Hosomi S, Tarumi K, Watanabe C, Saito M, Yokoyama Y, Inaba T, Sakata Y, Hongo H, Shibuya T, Kawakami K, Kakuta Y, Irisawa A, Yoshimura N, Fukuda K, Shirai T, Ichikawa H, Nagata J, Suzuki T, Yokoyama K, Tomidokoro T, Kojima Y, Yamada M, Yamamoto H, Yamamoto T, Horiki N, Obata H, Inoue S, Tanaka S, Toyokawa T, Kunihiro M, Hisabe T, Ogata S, Takeshima F, Matsushima K, Matsuhashi N, Sakuraba H, Iwabuchi M, Tsuchiya A, Uchiyama K, Kanai T, Nakamura M, Yokoyama T, Hida N, Mitsuyama K, Osada T, Hiraoka S, Tsuzuki T, Masuo T, Hokari R, Kobayashi T, Saruta M, Araki M, Araki H, Shimizu M, Kikuchi M, Nishikawa T, Takedatsu H, Aoyagi K, Ochiai T, Toda N, Mizokami Y, Nagahori M, Matsueda K, Kino H, Kanamori A, Suzuki T, Sakurai T, Kudo M, Kitano A, Hisamatsu T, Kumagai S, Ninomiya T, Mori K, Yoshida S, Goto M. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Gastroenterology & Hepatology 2022;7:648-57. [DOI: 10.1016/s2468-1253(22)00022-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
17 Saito J, Kaneko K, Kawasaki H, Hayakawa T, Yakuwa N, Suzuki T, Sago H, Yamatani A, Murashima A. Ustekinumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum. J Pharm Health Care Sci 2022;8:18. [PMID: 35773736 DOI: 10.1186/s40780-022-00249-8] [Reference Citation Analysis]
18 Salavatizadeh M, Soltanieh S, Chegini M, Ilesanmi-oyelere BL, Kord-varkaneh H, Hekmatdoost A. Micronutrient intake and risk of ulcerative colitis: A meta-analysis of observational studies. Clinical Nutrition ESPEN 2022. [DOI: 10.1016/j.clnesp.2022.07.008] [Reference Citation Analysis]
19 Malloy C, Rawl SM, Miller WR. Inflammatory Bowel Disease Self-Management. Gastroenterology Nursing 2022;45:254-266. [DOI: 10.1097/sga.0000000000000657] [Reference Citation Analysis]
20 Ohwada S, Ishigami K, Akutsu N, Nakase H. Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis. Biomedicines 2022;10:1334. [DOI: 10.3390/biomedicines10061334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Okabayashi S, Yamazaki H, Tominaga K, Miura M, Sagami S, Matsuoka K, Yamaguchi Y, Noake T, Ozeki K, Miyazaki R, Kamano T, Fukuda T, Yoshioka K, Ando K, Fukuzawa M, Andoh A, Yamamoto Y, Hibi T, Kobayashi T; IBD Terakoya Group. Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. Aliment Pharmacol Ther 2022;55:1569-80. [PMID: 35274323 DOI: 10.1111/apt.16865] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Yoshida A, Kimura K, Morizane T, Ueno F. Predictor of primary response to antitumor necrosis factor-α therapy for inflammatory bowel disease: a single-center observational study. Eur J Gastroenterol Hepatol 2022;34:640-5. [PMID: 35352693 DOI: 10.1097/MEG.0000000000002372] [Reference Citation Analysis]
23 Otake-kasamoto Y, Kayama H, Kishikawa T, Shinzaki S, Tashiro T, Amano T, Tani M, Yoshihara T, Li B, Tani H, Liu L, Hayashi A, Okuzaki D, Motooka D, Nakamura S, Okada Y, Iijima H, Takeda K, Takehara T. Lysophosphatidylserines derived from microbiota in Crohn’s disease elicit pathological Th1 response. Journal of Experimental Medicine 2022;219:e20211291. [DOI: 10.1084/jem.20211291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Mota J, Casimiro S, Fernandes J, Hartmann RM, Schemitt E, Picada J, Costa L, Marroni N, Raymundo A, Lima A, Ferreira RB. Lupin Protein Concentrate as a Novel Functional Food Additive That Can Reduce Colitis-Induced Inflammation and Oxidative Stress. Nutrients 2022;14:2102. [PMID: 35631241 DOI: 10.3390/nu14102102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Oncel S, Basson MD. Gut homeostasis, injury, and healing: New therapeutic targets. World J Gastroenterol 2022; 28(17): 1725-1750 [DOI: 10.3748/wjg.v28.i17.1725] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Mohanbhai SJ, Sardoiwala MN, Gupta S, Shrimali N, Choudhury SR, Sharma SS, Guchhait P, Karmakar S. Colon targeted chitosan-melatonin nanotherapy for preclinical Inflammatory Bowel Disease. Biomaterials Advances 2022;136:212796. [DOI: 10.1016/j.bioadv.2022.212796] [Reference Citation Analysis]
27 Sagami S, Kobayashi T, Aihara K, Umeda M, Odajima K, Morikubo H, Asonuma K, Miyatani Y, Fukuda T, Matsubayashi M, Kiyohara H, Nakano M, Hibi T. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Aliment Pharmacol Ther 2022;55:1320-9. [PMID: 35218038 DOI: 10.1111/apt.16817] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 M’koma AE. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina 2022;58:567. [DOI: 10.3390/medicina58050567] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Miro S, Amir A, Zubir N, Putra AE. Differences in MUC2 Gene Expression Based on the Clinical Severity of Colitis and the Degree of Histopathological Damage to the Colonic Mucosa in Colitis-induced Rat. Open Access Maced J Med Sci 2022;10:1170-1175. [DOI: 10.3889/oamjms.2022.8963] [Reference Citation Analysis]
30 Zamani M, Alizadeh-Tabari S, Singh S, Loomba R. Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2022;55:894-907. [PMID: 35274325 DOI: 10.1111/apt.16879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Amano T, Shinzaki S, Asakura A, Tashiro T, Tani M, Otake Y, Yoshihara T, Iwatani S, Yamada T, Sakakibara Y, Osugi N, Ishii S, Egawa S, Araki M, Arimoto Y, Nakahara M, Murayama Y, Kobayashi I, Kinoshita K, Ogawa H, Hiyama S, Shibukawa N, Komori M, Okuda Y, Kizu T, Yoshii S, Tsujii Y, Hayashi Y, Inoue T, Iijima H, Takehara T. Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease. Sci Rep 2022;12:5324. [PMID: 35351986 DOI: 10.1038/s41598-022-09455-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Li W, Zhang L, Xu Q, Yang W, Zhao J, Ren Y, Yu Z, Ma L. Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid. Nutrients 2022;14:1069. [DOI: 10.3390/nu14051069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
33 Battat R, Galati JS, Lukin D, Chabouni F, Sockolow R, Carter J, Fajardo K, Yang S, Reich J, Jacobs V, Abramowitz M, Kumar A, Christos P, Longman RS, Burakoff R, Simone L, Sapir T, Crawford CV, Scherl EJ. A Quality Improvement Initiative Is Associated With Reduced Time to Administer Biologics and Small Molecules and Emergency Room Visits in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology 2022;56:e176-e182. [DOI: 10.1097/mcg.0000000000001535] [Reference Citation Analysis]
34 Wenzel TJ, Haskey N, Kwong E, Greuel BK, Gates EJ, Gibson DL, Klegeris A. Dietary fats modulate neuroinflammation in mucin 2 knock out mice model of spontaneous colitis. Biochim Biophys Acta Mol Basis Dis 2022;1868:166336. [PMID: 34973372 DOI: 10.1016/j.bbadis.2021.166336] [Reference Citation Analysis]
35 Wang H, He X, Liang S, Chen X. Role of vitamin D in ulcerative colitis: an update on basic research and therapeutic applications. Expert Rev Gastroenterol Hepatol 2022;16:251-64. [PMID: 35236213 DOI: 10.1080/17474124.2022.2048817] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Tan C, Fan H, Ding J, Han C, Guan Y, Zhu F, Wu H, Liu Y, Zhang W, Hou X, Tan S, Tang Q. ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment. Materials Today Bio 2022;14:100246. [DOI: 10.1016/j.mtbio.2022.100246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
37 Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group (RECOVER). Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα. Gastroenterology 2022;162:454-67. [PMID: 34717923 DOI: 10.1053/j.gastro.2021.10.029] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 35.0] [Reference Citation Analysis]
38 Bargo D, Tritton T, Cappelleri JC, DiBonaventura M, Smith TW, Tsuchiya T, Gardiner S, Modesto I, Holbrook T, Bluff D, Kobayashi T. Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use. Inflamm Intest Dis 2021;6:186-98. [PMID: 35083284 DOI: 10.1159/000519123] [Reference Citation Analysis]
39 Madla CM, Gavins FKH, Trenfield SJ, Basit AW. Special Populations. Biopharmaceutics 2022. [DOI: 10.1002/9781119678366.ch13] [Reference Citation Analysis]
40 Endo K, Satoh T, Yoshino Y, Kondo S, Kawakami Y, Katayama T, Sasaki Y, Takasu A, Kogure T, Hirota M, Meguro T, Satoh K. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Noninvasive Predictors of the Therapeutic Outcomes of Systemic Corticosteroid Therapy in Ulcerative Colitis. Inflamm Intest Dis 2021;6:218-24. [PMID: 35083287 DOI: 10.1159/000520523] [Reference Citation Analysis]
41 Yano K, Moroi R, Shiga H, Tarasawa K, Shimoyama Y, Kuroha M, Hamada S, Kakuta Y, Fushimi K, Fujimori K, Kinouchi Y, Masamune A. Analysis of the disease activity of ulcerative colitis with and without concomitant primary sclerosing cholangitis: An investigation using a nationwide database in Japan. JGH Open 2022;6:50-6. [PMID: 35071788 DOI: 10.1002/jgh3.12693] [Reference Citation Analysis]
42 Cui Y, Yang M, Zhu J, Zhang H, Duan Z, Wang S, Liao Z, Liu W. Developments in diagnostic applications of saliva in Human Organ Diseases. Medicine in Novel Technology and Devices 2022. [DOI: 10.1016/j.medntd.2022.100115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
43 Tsuzuki Y, Shiomi R, Matsumoto H, Miyaguchi K, Kusano T, Ohgo H, Nakamoto H, Imaeda H. Combined effects of granulocyte and monocyte adsorption apheresis and corticosteroids on ulcerative colitis. J Clin Biochem Nutr 2022. [DOI: 10.3164/jcbn.22-52] [Reference Citation Analysis]
44 Isserman R, Mamula P, Litman RS. Gastrointestinal Diseases. Litman's Basics of Pediatric Anesthesia 2022. [DOI: 10.1016/b978-0-323-82902-1.00006-8] [Reference Citation Analysis]
45 El-sahhar S, Varga-weisz P. The gut microbiome in health and disease: Inflammatory bowel diseases. Advances in Ecological Research 2022. [DOI: 10.1016/bs.aecr.2022.09.005] [Reference Citation Analysis]
46 Kővári B, Pai RK. Upper Gastrointestinal Tract Involvement in Inflammatory Bowel Diseases: Histologic Clues and Pitfalls. Adv Anat Pathol 2022;29:2-14. [PMID: 34310370 DOI: 10.1097/PAP.0000000000000311] [Reference Citation Analysis]
47 Ceballos D, Hernández-Camba A, Ramos L. Diet and microbiome in the beginning of the sequence of gut inflammation. World J Clin Cases 2021; 9(36): 11122-11147 [DOI: 10.12998/wjcc.v9.i36.11122] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
48 Qiu P, Liu L, Fang J, Zhang M, Wang H, Peng Y, Chen M, Liu J, Wang F, Zhao Q. Identification of Pharmacological Autophagy Regulators of Active Ulcerative Colitis. Front Pharmacol 2021;12:769718. [PMID: 34925026 DOI: 10.3389/fphar.2021.769718] [Reference Citation Analysis]
49 Knyazev OV, Belousova EA, Abdulganieva DI, Gubonina IV, Kaibullayeva JA, Marakhouski YK, Chashkova EY, Shapina MV, Shchukina OB, Gegenava BB, Oliferuk NS. Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study. Alʹm klin med 2021;49:443-454. [DOI: 10.18786/2072-0505-2021-49-061] [Reference Citation Analysis]
50 Yao D, Dai W, Dong M, Dai C, Wu S. MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitis. EBioMedicine 2021;74:103751. [PMID: 34902790 DOI: 10.1016/j.ebiom.2021.103751] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
51 Marsh A, Rindfleish S, Bennett K, Croft A, Chachay V. Outcomes of dietary management approaches in active ulcerative colitis: A systematic review. Clin Nutr 2021;41:298-306. [PMID: 34999323 DOI: 10.1016/j.clnu.2021.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Saegusa Y, Imaizumi H, Kuwao S. Vedolizumab therapy in relatively patient with ulcerative colitis. Prog dig Endosc 2021;99:122-124. [DOI: 10.11641/pde.99.1_122] [Reference Citation Analysis]
53 Kuwabara H, Kimura H, Kunisaki R, Tatsumi K, Koganei K, Sugita A, Katsumata K, Tsuchida A, Endo I. Postoperative complications, bowel function, and prognosis in restorative proctocolectomy for ulcerative colitis-a single-center observational study of 320 patients. Int J Colorectal Dis 2021. [PMID: 34751417 DOI: 10.1007/s00384-021-04059-6] [Reference Citation Analysis]
54 Ogino H, Morikubo H, Fukaura K, Okui T, Gardiner S, Sugiyama N, Yoshii N, Kawaguchi T, Chen H, Nonnenmacher E, Setoguchi S, Nakashima N, Kobayashi T. Validation of a claims-based algorithm to identify cases of ulcerative colitis in Japan. J Gastroenterol Hepatol 2021. [PMID: 34738649 DOI: 10.1111/jgh.15732] [Reference Citation Analysis]
55 Mansour HH, Alajerami YS, Najim AA, Abushab KM. Computed Tomography Enterography Demonstrates Association to Histopathological Grading of Small Bowel Crohn’s Activity. ELECTRON J GEN MED 2021;18:em330. [DOI: 10.29333/ejgm/11317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Hishinuma K, Moroi R, Okamoto D, Shimoyama Y, Kuroha M, Shiga H, Kakuta Y, Kinouchi Y, Masamune A. Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation between Prognosis and Disease Susceptibility Loci. Inflamm Intest Dis 2021;6:154-64. [PMID: 34722645 DOI: 10.1159/000518371] [Reference Citation Analysis]
57 Benedik E, Urlep D, Orel A, Orel R. Partial Enteral Nutrition in Crohn’s Disease. Crohn’s Disease Recent Advances 2021. [DOI: 10.5772/intechopen.95385] [Reference Citation Analysis]
58 Shafiei SH, Nourbakhsh A, Vasigh M. An Enteric Fistula to a Hip Fusion Mass, 30 Years After the Arthrodesis: A Case Report. JBJS Case Connect 2021;11. [PMID: 34648472 DOI: 10.2106/JBJS.CC.21.00109] [Reference Citation Analysis]
59 Morikubo H, Kobayashi T, Fukuda T, Nagahama T, Hisamatsu T, Hibi T. Development of algorithms for identifying patients with Crohn's disease in the Japanese health insurance claims database. PLoS One 2021;16:e0258537. [PMID: 34644342 DOI: 10.1371/journal.pone.0258537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Tanaka Y, Takeuchi H, Nakashima Y, Nagano H, Ueno T, Tomizuka K, Morita S, Emi Y, Hamai Y, Hihara J, Saeki H, Oki E, Kunisaki C, Otsuji E, Baba H, Matsubara H, Maehara Y, Kitagawa Y, Yoshida K. Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5). ESMO Open 2021;6:100277. [PMID: 34626918 DOI: 10.1016/j.esmoop.2021.100277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
61 Tang S, Guo W, Kang L, Liang J. MiRNA-182-5p aggravates experimental ulcerative colitis via sponging Claudin-2. J Mol Histol 2021;52:1215-24. [PMID: 34623552 DOI: 10.1007/s10735-021-10021-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
62 Mitrev N, Huang H, Hannah B, Kariyawasam VC. Review of exclusive enteral therapy in adult Crohn's disease. BMJ Open Gastroenterol 2021;8:e000745. [PMID: 34580154 DOI: 10.1136/bmjgast-2021-000745] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
63 Chao K, Huang Y, Zhu X, Tang J, Wang X, Lin L, Guo H, Zhang C, Li M, Yang Q, Huang J, Ye L, Hu P, Huang M, Cao Q, Gao X. Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease. Aliment Pharmacol Ther 2021;54:1124-33. [PMID: 34563096 DOI: 10.1111/apt.16600] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
64 Shang X, Gu F, Bian Q, Wang M, Lin Z. Effects of a Written Expression-Based Positive Psychological Intervention on the Psychological Status of Patients With Inflammatory Bowel Disease: A Randomized Controlled Trial. Gastroenterol Nurs 2021;44:437-48. [PMID: 34560705 DOI: 10.1097/SGA.0000000000000594] [Reference Citation Analysis]
65 Kutsuna R, Miyoshi-Akiyama T, Tomida J, Kawamura Y. Draft Genome Sequence of Paraclostridium bifermentans subsp. muricolitidis Strain PAGU 1678T, Which Exacerbates Pathosis in a Mouse Model of Ulcerative Colitis. Microbiol Resour Announc 2021;10:e0078021. [PMID: 34528815 DOI: 10.1128/MRA.00780-21] [Reference Citation Analysis]
66 Okobi OE, Udoete IO, Fasehun OO, Okobi T, Evbayekha EO, Ekabua JJ, Elukeme H, Ebong IL, Ajayi OO, Olateju IV, Taiwo A, Anaya IC, Omole JA, Nkongho MB, Ojinnaka U, Ajibowo AO, Ogbeifun OE, Ugbo OO, Okorare O, Akinsola Z, Olusoji RA, Amanze IO, Nwafor JN, Ukoha NA, Elimihele TA. A Review of Four Practice Guidelines of Inflammatory Bowel Disease. Cureus 2021;13:e16859. [PMID: 34513436 DOI: 10.7759/cureus.16859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Edelman-klapper H, Zittan E, Shitrit AB, Rabinowitz KM, Goren I, Avni-biron I, Ollech JE, Lichtenstein L, Banai-eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-horin S, Perets T, Eliakim R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-tanamy M, Freund NT, Cohen D, Dotan I. Decreased Immune Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti TNFα.. [DOI: 10.1101/2021.08.22.21262263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Xi-Zhang, Yuan XQ, Zhang XM. Melatonin reduces inflammation in intestinal cells, organoids and intestinal explants. Inflammopharmacology 2021;29:1555-64. [PMID: 34431007 DOI: 10.1007/s10787-021-00869-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Zhou YF, Sun N, Cheng SR, Deng XD, Ye XY, Li ZJ, Zhou J, Xu GX, Qu YZ, Huang LY, Sun RR, Liang FR. Effectiveness and safety of acupuncture therapy for inflammatory bowel disease: a protocol of systematic review and meta-analysis. BMJ Open 2021;11:e045090. [PMID: 34429304 DOI: 10.1136/bmjopen-2020-045090] [Reference Citation Analysis]
70 Cheng Z, Si X, Tan H, Zang Z, Tian J, Shu C, Sun X, Li Z, Jiang Q, Meng X, Chen Y, Li B, Wang Y. Cyanidin-3-O-glucoside and its phenolic metabolites ameliorate intestinal diseases via modulating intestinal mucosal immune system: potential mechanisms and therapeutic strategies. Crit Rev Food Sci Nutr 2021;:1-19. [PMID: 34420433 DOI: 10.1080/10408398.2021.1966381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
71 Naganuma M, Watanabe K, Motoya S, Ogata H, Matsui T, Suzuki Y, Ursos L, Sakamoto S, Shikamura M, Hori T, Fernandez J, Watanabe M, Hibi T, Kanai T. Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. J Gastroenterol Hepatol 2021. [PMID: 34409654 DOI: 10.1111/jgh.15667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Caprioli F, Daperno M, Bravatà I, Brigido A, Frigerio D, Secchi O, Rispo A. Who are the patients with Crohn's disease unsuitable to receive an anti-TNFα therapy? Results from a survey of Italian physicians and literature review. Eur J Gastroenterol Hepatol 2021;33:1082-90. [PMID: 34213505 DOI: 10.1097/MEG.0000000000002183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Witges K, Sexton K, Graff LA, Targownik LE, Lix LM, Haviva C, Stone J, Shafer LA, Vagianos K, Bernstein CN. What Is a Flare? The Manitoba Living With IBD Study. Inflamm Bowel Dis 2021:izab192. [PMID: 34347048 DOI: 10.1093/ibd/izab192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
74 Madarame A, Fukuzawa M, Yamauchi Y, Kono S, Sugimoto A, Yamaguchi H, Morise T, Koyama Y, Uchida K, Suguro M, Matsumoto T, Yasuyuki K, Kawai T, Itoi T. Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase. PLoS One 2021;16:e0255620. [PMID: 34347848 DOI: 10.1371/journal.pone.0255620] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Liu J, Liu J, Tong X, Peng W, Wei S, Sun T, Wang Y, Zhang B, Li W. Network Pharmacology Prediction and Molecular Docking-Based Strategy to Discover the Potential Pharmacological Mechanism of Huai Hua San Against Ulcerative Colitis. Drug Des Devel Ther 2021;15:3255-76. [PMID: 34349502 DOI: 10.2147/DDDT.S319786] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
76 Matsuoka K, Ishikawa H, Nakayama T, Honzawa Y, Maemoto A, Hirai F, Ueno F, Sato N, Susuta Y, Hibi T. Physician-patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis. J Gastroenterol 2021;56:843-55. [PMID: 34313863 DOI: 10.1007/s00535-021-01811-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Miyazaki C, Katsumasa N, Huang KC, Liu YF. Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan. PLoS One 2021;16:e0254807. [PMID: 34280242 DOI: 10.1371/journal.pone.0254807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Galindo-rozo LV, Cáceres-escobar D, Suárez-quintero Y, Vargas-rubio RD, Ovalle-hernández AF. Ascitis en paciente con colitis ulcerativa como presentación de síndrome de Budd-Chiari: reporte de caso y revisión de la literatura. Hepatología 2021. [DOI: 10.52784/27112330.141] [Reference Citation Analysis]
79 Zhu M, Ran Z. Clinical characteristics of ulcerative colitis in elderly patients. JGH Open 2021;5:849-54. [PMID: 34386591 DOI: 10.1002/jgh3.12612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 de Bock E, Filipe MD, Meij V, Oldenburg B, van Schaik FDM, Bastian OW, Fidder HF, Vriens MR, Richir MC. Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands. BMJ Open Gastroenterol 2021;8:e000670. [PMID: 34215570 DOI: 10.1136/bmjgast-2021-000670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Weissman S, Systrom HK, Aziz M, El-Dallal M, Lee-Smith W, Sciarra M, Feuerstein JD. Colorectal Cancer Prevention in Inflammatory Bowel Disease: A Systematic Analysis of the Overall Quality of Guideline Recommendations. Inflamm Bowel Dis 2021:izab164. [PMID: 34245270 DOI: 10.1093/ibd/izab164] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Kasuga K, Yamada M, Shida D, Tagawa T, Takamaru H, Sekiguchi M, Sakamoto T, Uraoka T, Sekine S, Kanemitsu Y, Saito Y. Treatment outcomes of endoscopic submucosal dissection and surgery for colorectal neoplasms in patients with ulcerative colitis. United European Gastroenterol J 2021. [PMID: 34232561 DOI: 10.1002/ueg2.12118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
83 Mizushima T, Ota M, Fujitani Y, Kanauchi Y, Iwakiri R. Diagnostic Features of Perianal Fistula in Patients With Crohn’s Disease: Analysis of a Japanese Claims Database. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab055] [Reference Citation Analysis]
84 Itabashi M, Ikeuchi H, Kimura H, Fukushima K, Fujii H, Nezu R, Futami K, Sugita A, Suzuki Y, Hisamatsu T. Perioperative Venous Thromboembolism in Ulcerative Colitis: A Multicenter Prospective Study in Japan. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab024] [Reference Citation Analysis]
85 Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. Drug development for ulcerative proctitis: current concepts. Gut 2021;70:1203-9. [PMID: 33789968 DOI: 10.1136/gutjnl-2021-324108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
86 Takeda T, Kishi M, Takatsu N, Takada Y, Beppu T, Miyaoka M, Hisabe T, Ueki T, Arima H, Hirai F, Yao K. Long-term outcomes of endoscopic balloon dilation for intestinal strictures in patients with Crohn's disease during maintenance treatment with anti-tumor necrosis factor alpha antibodies. Dig Endosc 2021. [PMID: 34185921 DOI: 10.1111/den.14073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
87 Stange EF. Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations. Z Gastroenterol 2021. [PMID: 34161990 DOI: 10.1055/a-1482-9273] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Yoshida A, Matsuoka K, Ueno F, Morizane T, Endo Y, Hibi T. Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis. Inflamm Intest Dis 2021;6:117-22. [PMID: 34124183 DOI: 10.1159/000515361] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
89 Yu D, Zhao Y, Wang H, Kong D, Jin W, Hu Y, Qin Y, Zhang B, Li X, Hao J, Li G, Wang H. IL-1β pre-stimulation enhances the therapeutic effects of endometrial regenerative cells on experimental colitis. Stem Cell Res Ther 2021;12:324. [PMID: 34090510 DOI: 10.1186/s13287-021-02392-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
90 Karpova RV, Russkova KS, Komarov RN, Petrova AA. Ultrasound-Guided Percutaneous Drainage of Abdominal Abscess in a Patient With Crohn's Disease: A Case Report. Front Surg 2021;8:616586. [PMID: 34150835 DOI: 10.3389/fsurg.2021.616586] [Reference Citation Analysis]
91 Guan Y, Hao Y, Guan Y, Bu H, Wang H. Effects of vitamin D supplementation on blood markers in ulcerative colitis patients: a systematic review and meta-analysis. Eur J Nutr 2021. [PMID: 34075433 DOI: 10.1007/s00394-021-02603-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Sehgal K, Yadav D, Khanna S. The interplay of Clostridioides difficile infection and inflammatory bowel disease. Therap Adv Gastroenterol 2021;14:17562848211020285. [PMID: 34104215 DOI: 10.1177/17562848211020285] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
93 Vohra I, Attar B, Haghbin H, Mutneja H, Katiyar V, Sharma S, Abegunde AT, Demetria M, Gandhi S. Incidence and risk factors for 30-day readmission in ulcerative colitis: nationwide analysis in biologic era. Eur J Gastroenterol Hepatol 2021;33:1174-84. [PMID: 34034271 DOI: 10.1097/MEG.0000000000002147] [Reference Citation Analysis]
94 Kiss S, Németh D, Hegyi P, Földi M, Szakács Z, Erőss B, Tinusz B, Hegyi PJ, Sarlós P, Alizadeh H. Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis. BMJ Open 2021;11:e042374. [PMID: 34011580 DOI: 10.1136/bmjopen-2020-042374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Bromke MA, Neubauer K, Kempiński R, Krzystek-Korpacka M. Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis. J Clin Med 2021;10:2203. [PMID: 34069684 DOI: 10.3390/jcm10102203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
96 Xiao BH, Ma XD, Lv JJ, Yang T, Liu XJ, An LY, Qi YX, Lu ML, Duan YQ, Sun DL. Systematic evaluation of the diagnostic approach of inflammatory bowel disease guidelines. Int J Clin Pract 2021;:e14365. [PMID: 34008296 DOI: 10.1111/ijcp.14365] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Thomson P, Núñez P, Quera R, Bay C. Gastrointestinal microbiome, what is behind faecal microbiota transplantation? New Microbes New Infect 2021;42:100898. [PMID: 34168881 DOI: 10.1016/j.nmni.2021.100898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Wang P, Chen Y, Zhang LM, Yuan SQ, Lu SA, Zhang YJ. Effect of MicroRNA145 on the multidrug resistance gene of ulcerative colitis in rats. Life Sci 2021;278:119603. [PMID: 33984358 DOI: 10.1016/j.lfs.2021.119603] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Giang J, Lan X, Crichton M, Marx W, Marshall S. Efficacy and safety of biophenol-rich nutraceuticals in adults with inflammatory gastrointestinal diseases or irritable bowel syndrome: A systematic literature review and meta-analysis. Nutr Diet 2021. [PMID: 33960587 DOI: 10.1111/1747-0080.12672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
100 Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T, Shiotani A, Hirai F, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J Gastroenterol 2021;56:560-9. [PMID: 33942166 DOI: 10.1007/s00535-021-01793-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
101 Miyazaki C, Sakashita T, Jung W, Kato S. Real-World Prescription Pattern and Healthcare Cost Among Patients with Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis. Adv Ther 2021;38:2229-47. [PMID: 33515423 DOI: 10.1007/s12325-020-01615-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
102 Wang Y, Liu K, Qi Z, Chen T, Yu W, Jiang Y, Li G, Xiao H. Therapeutic Mechanism and Effect of Camptothecin on Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice. J Immunol Res 2021;2021:5556659. [PMID: 33987448 DOI: 10.1155/2021/5556659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
103 Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 2021;6:429-37. [PMID: 33887262 DOI: 10.1016/S2468-1253(21)00062-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
104 Demirtas A. The lived experiences of people with inflammatory bowel diseases: A phenomenological hermeneutic study. Int J Nurs Pract 2021;:e12946. [PMID: 33864417 DOI: 10.1111/ijn.12946] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Kobayashi T, Uda A, Udagawa E, Hibi T. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. J Crohns Colitis 2020;14:617-23. [PMID: 31867632 DOI: 10.1093/ecco-jcc/jjz204] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
106 Asonuma K, Kobayashi T, Nakano M, Sagami S, Kiyohara H, Matsubayashi M, Morikubo H, Miyatani Y, Okabayashi S, Yamazaki H, Kuroki Y, Hibi T. Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. Inflamm Bowel Dis 2021:izab062. [PMID: 33847348 DOI: 10.1093/ibd/izab062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
107 Omori T, Saruta M, Nagaki A, Arai Y, Ohta A, Kuramoto K, Suzuki Y. Real-world safety and efficacy of twice-daily budesonide 2-mg foam in patients with ulcerative colitis: interim analysis of post-marketing surveillance. Expert Opin Pharmacother 2021;22:1505-11. [PMID: 33832402 DOI: 10.1080/14656566.2021.1905796] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Kunogi Y, Tominaga K, Abe K, Kanazawa M, Tanaka T, Watanabe S, Kondo M, Kanamori A, Iijima M, Goda K, Nozawa Y, Ishida K, Irisawa A. Refractory Immune Checkpoint Inhibitor-Induced Colitis Improved by Tacrolimus: A Case Report. Healthcare (Basel) 2021;9:418. [PMID: 33916353 DOI: 10.3390/healthcare9040418] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
109 Moroi R, Shiga H, Tarasawa K, Yano K, Shimoyama Y, Kuroha M, Kakuta Y, Fushimi K, Fujimori K, Kinouchi Y, Masamune A. The clinical practice of ulcerative colitis in elderly patients: An investigation using a nationwide database in Japan. JGH Open 2021;5:842-8. [PMID: 34386590 DOI: 10.1002/jgh3.12541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
110 Matsuoka K, Naganuma M, Hibi T, Tsubouchi H, Oketani K, Katsurabara T, Hojo S, Takenaka O, Kawano T, Imai T, Kanai T. Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease. J Gastroenterol Hepatol 2021;36:2180-6. [PMID: 33599356 DOI: 10.1111/jgh.15463] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
111 Ali FEM, M Elfiky M, Fadda WA, Ali HS, Mahmoud AR, Mohammedsaleh ZM, Abd-Elhamid TH. Regulation of IL-6/STAT-3/Wnt axis by nifuroxazide dampens colon ulcer in acetic acid-induced ulcerative colitis model: Novel mechanistic insight. Life Sci 2021;276:119433. [PMID: 33794250 DOI: 10.1016/j.lfs.2021.119433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
112 Cheng H, Ma Z, Yu B, Liu X, Tian C, Zhong X, Zhao L. Quality assessment of clinical guidelines on probiotics therapy in children with IBD using the AGREE II instrument. J Clin Pharm Ther 2021;46:1155-65. [PMID: 33768598 DOI: 10.1111/jcpt.13422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
113 Takeyama E, Wada H, Sato S, Tomooka K, Ikeda A, Tanigawa T. Association of diagnostic delay with medical cost for patients with Crohn's disease: A Japanese claims-based cohort study. JGH Open 2021;5:568-72. [PMID: 34013056 DOI: 10.1002/jgh3.12534] [Reference Citation Analysis]
114 Horio Y, Uchino M, Kihara T, Bando T, Kuwahara R, Minagawa T, Kusunoki K, Watanabe K, Hirota S, Ikeuchi H. Potential problems of partial resection for colitis-associated cancer in a patient with ulcerative colitis: case report. J Surg Case Rep 2021;2021:rjab086. [PMID: 33777355 DOI: 10.1093/jscr/rjab086] [Reference Citation Analysis]
115 Baranov AA, Namazova-baranova LS, Alexeeva AA, Ambarchian ET, Aslamazyan LK, Astafieva NG, Balykova LA, Belyaeva IA, Bulgakova VA, Vakhlova IV, Vashakmadze ND, Vishneva EA, Getiya EG, Il’ina NI, Kaytukova EV, Kamaltynova EM, Karkashadze GA, Kovtun OP, Komarova EV, Kulichenko TV, Kurbacheva OM, Levina YG, Makarova SG, Murashkin NN, Nesterova YV, Novik GA, Piskunova SG, Popova LY, Privalova TE, Selimzyanova LR, Sergienko NS, Serebryakova EN, Stasiy ED, Tkachenko MA, Turti TV, Ustinova NV, Fedorova OS, Fomina DS, Fugol’ DS, Chemakina DS, Shepeleva IM, Efendieva KE. Amino Acid Formulas in Patients with Gastrointestinal Diseases. Pediatr farmakol 2021;18:38-47. [DOI: 10.15690/pf.v18i1.2222] [Reference Citation Analysis]
116 Zeng W, He D, Xing Y, Liu J, Su N, Zhang C, Wang Y, Xing X. Internal connections between dietary intake and gut microbiota homeostasis in disease progression of ulcerative colitis: a review. Food Science and Human Wellness 2021;10:119-30. [DOI: 10.1016/j.fshw.2021.02.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
117 Zhang ZJ, Qu HL, Zhao N, Wang J, Wang XY, Hai R, Li B. Assessment of Causal Direction Between Gut Microbiota and Inflammatory Bowel Disease: A Mendelian Randomization Analysis. Front Genet 2021;12:631061. [PMID: 33679893 DOI: 10.3389/fgene.2021.631061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
118 Franzin M, Stefančič K, Lucafò M, Decorti G, Stocco G. Microbiota and Drug Response in Inflammatory Bowel Disease. Pathogens 2021;10:211. [PMID: 33669168 DOI: 10.3390/pathogens10020211] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
119 Okuno H, Ogino H, Ihara E, Nishioka K, Tanaka Y, Chinen T, Kohjima M, Oono T, Tanaka M, Goya T, Fujimori N, Iboshi Y, Gotoda T, Ogawa Y. Discriminant equation using mucosally expressed cytokines and transcription factor for making definite diagnosis of inflammatory bowel disease unclassified. BMC Gastroenterol 2021;21:73. [PMID: 33593285 DOI: 10.1186/s12876-021-01656-1] [Reference Citation Analysis]
120 Naftali T, Bar-Lev Schleider L, Scklerovsky Benjaminov F, Konikoff FM, Matalon ST, Ringel Y. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial. PLoS One 2021;16:e0246871. [PMID: 33571293 DOI: 10.1371/journal.pone.0246871] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
121 Meima-van Praag EM, Buskens CJ, Hompes R, Bemelman WA. Surgical management of Crohn's disease: a state of the art review. Int J Colorectal Dis 2021;36:1133-45. [PMID: 33528750 DOI: 10.1007/s00384-021-03857-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
122 Adamkova P, Hradicka P, Gancarcikova S, Kassayova M, Ambro L, Bertkova I, Maronek M, Farkasova Iannaccone S, Demeckova V. Single Donor FMT Reverses Microbial/Immune Dysbiosis and Induces Clinical Remission in a Rat Model of Acute Colitis. Pathogens 2021;10:152. [PMID: 33540919 DOI: 10.3390/pathogens10020152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
123 Sagami S, Nishikawa K, Yamada F, Suzuki Y, Watanabe M, Hibi T. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. J Gastroenterol Hepatol 2021;36:2091-100. [PMID: 33450057 DOI: 10.1111/jgh.15399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
124 Tominaga K, Sugaya T, Tanaka T, Kanazawa M, Iijima M, Irisawa A. Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:582291. [PMID: 33584261 DOI: 10.3389/fphar.2020.582291] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
125 Morikubo H, Kobayashi T, Ozaki R, Okabayashi S, Kuronuma S, Takeuchi O, Shiba T, Kiyohara H, Matsubayashi M, Sagami S, Nakano M, Ikezaki O, Hisamatsu T, Tanaka Y, Hibi T. Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition. J Gastroenterol Hepatol 2021;36:2116-24. [PMID: 33470487 DOI: 10.1111/jgh.15411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
126 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
127 Suzuki K, Kakuta Y, Naito T, Takagawa T, Hanai H, Araki H, Sasaki Y, Sakuraba H, Sasaki M, Hisamatsu T, Motoya S, Matsumoto T, Onodera M, Ishiguro Y, Nakase H, Andoh A, Hiraoka S, Shinozaki M, Fujii T, Katsurada T, Kobayashi T, Fujiya M, Otsuka T, Oshima N, Suzuki Y, Sato Y, Hokari R, Noguchi M, Ohta Y, Matsuura M, Kawai Y, Tokunaga K, Nagasaki M, Kudo H, Minegishi N, Okamoto D, Shimoyama Y, Moroi R, Kuroha M, Shiga H, Li D, McGovern DPB, Kinouchi Y, Masamune A; MENDEL study group . Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab004. [PMID: 33501934 DOI: 10.1093/ibd/izab004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
128 Peppas S, Pansieri C, Piovani D, Danese S, Peyrin-Biroulet L, Tsantes AG, Brunetta E, Tsantes AE, Bonovas S. The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases. J Clin Med 2021;10:377. [PMID: 33498197 DOI: 10.3390/jcm10030377] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
129 Ratajczak AE, Szymczak-Tomczak A, Zawada A, Rychter AM, Dobrowolska A, Krela-Kaźmierczak I. Does Drinking Coffee and Tea Affect Bone Metabolism in Patients with Inflammatory Bowel Diseases? Nutrients 2021;13:216. [PMID: 33451170 DOI: 10.3390/nu13010216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
130 Fukushima S, Shiotani A, Matsumoto H, Handa O, Handa Y, Osawa M, Murao T, Umegaki E, Kawano M, Inoue R, Naito Y. Comparison of mucosa-associated microbiota in Crohn’s disease patients with and without anti-tumor necrosis factor-α therapy. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-41] [Reference Citation Analysis]
131 Takayama K, Ito K, Matsui A, Yamashita T, Kawakami K, Hirayama D, Kishimoto W, Nakase H, Mizuguchi H. In Vivo Gene Expression Profile of Human Intestinal Epithelial Cells: From the Viewpoint of Drug Metabolism and Pharmacokinetics. Drug Metab Dispos 2021;49:221-32. [DOI: 10.1124/dmd.120.000283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
132 Del Pinto R, Pietropaoli D, Monaco A, Desideri G, Ferri C, Grassi D. Non-pharmacological Strategies Against Systemic Inflammation: Molecular Basis and Clinical Evidence. Curr Pharm Des 2020;26:2620-9. [PMID: 32242777 DOI: 10.2174/1381612826666200403122600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
133 Zuluaga Arbeláez N, Sierra Vargas EC, Díaz Coronado JC, Guevara Casallas LG. Colitis ulcerativa para no gastroenterólogos. CES Med 2020;34:188-197. [DOI: 10.21615/cesmedicina.34.3.2] [Reference Citation Analysis]
134 Tamura S, Ishida N, Miyazu T, Onoue S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation. Sci Rep 2020;10:21353. [PMID: 33288852 DOI: 10.1038/s41598-020-78603-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
135 Hosseini-Asl SK, Mehrabani D, Karimi-Busheri F. Therapeutic Effect of Mesenchymal Stem Cells in Ulcerative Colitis: A Review on Achievements and Challenges. J Clin Med 2020;9:E3922. [PMID: 33287220 DOI: 10.3390/jcm9123922] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
136 Hernandez L, Kuwabara H, Shah A, Yamabe K, Burnett H, Fahrbach K, Koufopoulou M, Iwakiri R. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. Pharmacoeconomics 2020;38:69-84. [PMID: 31552601 DOI: 10.1007/s40273-019-00841-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
137 Ogata H, Hagiwara T, Kawaberi T, Kobayashi M, Hibi T. Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. Intest Res 2021;19:419-29. [PMID: 33166442 DOI: 10.5217/ir.2020.00033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
138 Tominaga K, Kanazawa M, Tanaka T, Kojimahara S, Sugaya T, Watanabe S, Yamamiya A, Majima Y, Iijima M, Goda K, Irisawa A. A Case of Lung Abscess Caused by Double Immunosuppressive Therapy to Treat Ulcerative Colitis. Medicina 2020;56:595. [DOI: 10.3390/medicina56110595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
139 Song JH, Kim JW, Oh CH, Kim HJ, Lee CK, Kang WS. Depression, Anxiety, Related Risk Factors and Cognitive Distortion in Korean Patients with Inflammatory Bowel Disease. Psychiatry Investig 2020;17:1126-36. [PMID: 33115188 DOI: 10.30773/pi.2020.0299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
140 Bogach J, Wright FC, Austin J, Cheng SY, Diong C, Sutradhar R, Baxter NN, Look Hong NJ. Medical Immunosuppression and Outcomes in Cutaneous Melanoma: A Population-Based Cohort Study. Ann Surg Oncol 2021;28:3302-11. [PMID: 33067747 DOI: 10.1245/s10434-020-09224-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Ikeuchi A, Kakiuchi T, Ibi A, Matsuo M. A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan. Clin J Gastroenterol 2021;14:146-51. [PMID: 33040281 DOI: 10.1007/s12328-020-01260-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
142 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 20.0] [Reference Citation Analysis]
143 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 260] [Cited by in F6Publishing: 276] [Article Influence: 130.0] [Reference Citation Analysis]
144 Nakase H, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Wagatsuma K, Yokoyama Y, Hisamatsu T. Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research. Digestion. 2020;1-9. [PMID: 32892197 DOI: 10.1159/000510502] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
145 Matsubayashi M, Kobayashi T, Okabayashi S, Nakano M, Sagami S, Ozaki R, Kiyohara H, Morikubo H, Asonuma K, Miyatani Y, Maeda S, Hibi T. Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. J Gastroenterol Hepatol 2021;36:943-50. [PMID: 32805065 DOI: 10.1111/jgh.15220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
146 Saad HM, Ali E, Baddour N, Ibrahim ME, Tayae E. Serum expression of microRNA-16 in a cohort of Egyptian patients with ulcerative colitis and its correlation with disease extent and severity. Journal of Coloproctology 2020;40:253-260. [DOI: 10.1016/j.jcol.2020.05.013] [Reference Citation Analysis]
147 Matsuoka K, Igarashi A, Sato N, Isono Y, Gouda M, Iwasaki K, Shoji A, Hisamatsu T. Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data from 2006 to 2016. J Crohns Colitis 2021;15:358-66. [PMID: 32845311 DOI: 10.1093/ecco-jcc/jjaa172] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
148 Goulart RDA, Barbalho SM, Rubira CJ, Araújo AC, Lima VM, Buchaim RL, Guiguer EL. Curcumin therapy for ulcerative colitis remission: systematic review and meta-analysis. Expert Review of Gastroenterology & Hepatology 2020;14:1171-9. [DOI: 10.1080/17474124.2020.1808460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
149 Hayashida S, Sato S, Shimada Y, Tsuzura H, Ikeda Y, Takahashi S, Sato S, Amano N, Murata A, Nagahara A, Genda T. Eosinophilic Gastroenteritis in an Ulcerative Colitis Patient During Treatment with Tumor Necrosis Factor-alpha Antagonist. Intern Med 2020;59:1977-81. [PMID: 32801271 DOI: 10.2169/internalmedicine.4554-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
150 Goss M, Weinheimer K, Weinheimer RA, Schade MA, Davis CM 3rd, Garner MR. Septic Arthritis of the Hip and Enterocutaneous Fistula Formation After Hip Arthroscopy: A Case Report of Psoas Abscess Misdiagnosed as Labral Pathology. JBJS Case Connect 2019;9:e0505. [PMID: 31815807 DOI: 10.2106/JBJS.CC.18.00505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Wang Q, Mi S, Yu Z, Li Q, Lei J. Opening a Window on Attention: Adjuvant Therapies for Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2020;2020:7397523. [PMID: 32850517 DOI: 10.1155/2020/7397523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Naganuma M. Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis. J Gastroenterol 2020;55:1013-22. [PMID: 32778960 DOI: 10.1007/s00535-020-01713-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
153 Sagami S, Kobayashi T, Miyatani Y, Okabayashi S, Yamazaki H, Takada T, Kinoshita K, Allocca M, Kunisaki R, Ramaswamy PK, Shiraki M, Hibi T, Kataoka Y. Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:908-921.e6. [PMID: 32777549 DOI: 10.1016/j.cgh.2020.07.067] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
154 Jia D, Dou Y, Li Z, Zhou X, Gao Y, Chen K, Cong W, Ma M, Wu Z, Li W. Design, synthesis and evaluation of a baicalin and berberine hybrid compound as therapeutic agent for ulcerative colitis. Bioorg Med Chem 2020;28:115697. [PMID: 33069077 DOI: 10.1016/j.bmc.2020.115697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
155 Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology 2020;159:481-491.e3. [PMID: 32425234 DOI: 10.1053/j.gastro.2020.05.032] [Cited by in Crossref: 467] [Cited by in F6Publishing: 485] [Article Influence: 233.5] [Reference Citation Analysis]
156 Oka A, Sartor RB. Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases. Dig Dis Sci. 2020;65:757-788. [PMID: 32006212 DOI: 10.1007/s10620-020-06090-z] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 32.0] [Reference Citation Analysis]
157 Kitayama M, Akazawa Y, Yoshikawa D, Higashi S, Morisaki T, Oda H, Ikeda M, Nakashima Y, Tabuchi M, Hashiguchi K, Matsushima K, Yamaguchi N, Kondo H, Nakao K, Takeshima F. Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients. Sci Rep 2020;10:12546. [PMID: 32719413 DOI: 10.1038/s41598-020-68828-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Mees M, Meurer MC, Mariano LNB, Boeing T, Somensi LB, Mariott M, Niero R, Cechinel-Filho V, Andrade SF, Duarte LP, Sousa GF, de Souza P, Da Silva LM. Maytenus robusta Reissek, a medicinal plant popularly used to treat digestive diseases, promotes ameliorative effects in colon and liver of mice exposed to dextran sulfate sodium. J Ethnopharmacol 2020;261:113180. [PMID: 32730884 DOI: 10.1016/j.jep.2020.113180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
159 Suzuki H, Joshita S, Hirayama A, Shinji A, Mukawa K, Sako M, Yoshimura N, Suga T, Umemura T, Ashihara N, Yamazaki T, Ota M. Polymorphism at rs9264942 is associated with HLA-C expression and inflammatory bowel disease in the Japanese. Sci Rep 2020;10:12424. [PMID: 32709981 DOI: 10.1038/s41598-020-69370-8] [Reference Citation Analysis]
160 Orihara Y, Asakura M, Hida N, Kawai M, Sato T, Nishimura K, Masai K, Matsumoto Y, Okuhara Y, Goda A, Masuyama T, Nakamura S, Ishihara M. Effect of Oral Qing-Dai Medication on Pulmonary Arterial Pressure Levels in Patients With Ulcerative Colitis. Circ J 2020;84:1339-1345. [DOI: 10.1253/circj.cj-19-1112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Hata K, Ishihara S, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Kunisaki R, Nakase H, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Shinozaki M, Ogata N, Moriichi K, Hirai F, Sugihara K, Hisamatsu T, Suzuki Y, Watanabe M, Hibi T. Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy. J Clin Med 2020;9:E2286. [PMID: 32708456 DOI: 10.3390/jcm9072286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
162 Okamoto D, Kawai Y, Kakuta Y, Naito T, Torisu T, Hirano A, Umeno J, Fuyuno Y, Li D, Nakano T, Izumiyama Y, Ichikawa R, Hiramoto K, Moroi R, Kuroha M, Kanazawa Y, Shiga H, Tokunaga K, Nakamura M, Esaki M, Matsumoto T, McGovern DPB, Nagasaki M, Kinouchi Y, Masamune A. Genetic Analysis of Ulcerative Colitis in Japanese Individuals Using Population-specific SNP Array. Inflamm Bowel Dis 2020;26:1177-87. [PMID: 32072174 DOI: 10.1093/ibd/izaa033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
163 Palchaudhuri S, Albenberg L, Lewis JD. Diet Recommendations for Hospitalized Patients With Inflammatory Bowel Disease: Better Options Than Nil Per Os. Crohns Colitis 360 2020;2:otaa059. [PMID: 33954288 DOI: 10.1093/crocol/otaa059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
164 Higashiyama M, Komoto S, Suzuki Y, Watanabe M, Hibi T, Miura S, Hokari R. Relation of geriatric nutritional risk index with clinical risks in elderly-onset ulcerative colitis. J Gastroenterol Hepatol 2021;36:163-70. [PMID: 32583472 DOI: 10.1111/jgh.15161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Kimura K, Yoshida A, Katagiri F, Takayanagi R, Yamada Y. Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling. Eur J Pharm Sci 2020;150:105317. [PMID: 32205229 DOI: 10.1016/j.ejps.2020.105317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
166 Iijima H, Kobayashi T, Nagasaka M, Shinzaki S, Kitamura K, Suzuki Y, Watanabe M, Hibi T. Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn's Disease. Inflamm Intest Dis 2020;5:78-83. [PMID: 32596258 DOI: 10.1159/000506337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
167 Lin L, Zhou G, Chen P, Wang Y, Han J, Chen M, He Y, Zhang S. Which long noncoding RNAs and circular RNAs contribute to inflammatory bowel disease? Cell Death Dis 2020;11:456. [PMID: 32541691 DOI: 10.1038/s41419-020-2657-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
168 Gordon M, Grafton-clarke C, Akobeng A, Macdonald J, Chande N, Hanauer S, Arnott I. Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn’s disease: a systematic review. Frontline Gastroenterol 2021;12:423-36. [DOI: 10.1136/flgastro-2020-101405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
169 Matsuoka K. NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease. Intest Res 2020;18:275-81. [PMID: 32482022 DOI: 10.5217/ir.2020.00002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
170 Krzystek-Korpacka M, Kempiński R, Bromke M, Neubauer K. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics (Basel) 2020;10:E367. [PMID: 32498475 DOI: 10.3390/diagnostics10060367] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
171 Kobayashi M, Matsubara N, Nakachi Y, Okazaki Y, Uchino M, Ikeuchi H, Song J, Kimura K, Yasuhara M, Babaya A, Yamano T, Ikeda M, Nishikawa H, Matsuda I, Hirota S, Tomita N. Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer. In Vivo 2020;34:57-63. [PMID: 31882463 DOI: 10.21873/invivo.11745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
172 Dhindsa BS, Dhaliwal A, Mashiana HS, Saghir SM, Sayles H, Mubder M, Ohning G, Eichele D. Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: A systematic review and meta-analysis. Indian J Gastroenterol 2020;39:153-60. [DOI: 10.1007/s12664-020-01031-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
173 Thi Thanh Tran H, Saito S, Noto S, Suzuki K. Quality of Life and Eligibility for Specific Financial Assistance for Medical Expenses: A Cross-Sectional Web-Based Survey among Patients with Inflammatory Bowel Disease in Japan. GastrointestDisord 2020;2:123-33. [DOI: 10.3390/gidisord2020012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
174 Wizenty J, Schumann T, Theil D, Stockmann M, Pratschke J, Tacke F, Aigner F, Wuensch T. Recent Advances and the Potential for Clinical Use of Autofluorescence Detection of Extra-Ophthalmic Tissues. Molecules 2020;25:E2095. [PMID: 32365790 DOI: 10.3390/molecules25092095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
175 Iwatani S, Iijima H, Otake Y, Amano T, Tani M, Yoshihara T, Tashiro T, Tsujii Y, Inoue T, Hayashi Y, Takeda K, Hayashi A, Fujita S, Shinzaki S, Takehara T. Novel mass spectrometry‐based comprehensive lipidomic analysis of plasma from patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology 2020;35:1355-64. [DOI: 10.1111/jgh.15067] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
176 Morita Y, Bamba S, Inatomi O, Takahashi K, Imai T, Murata M, Ohno M, Sasaki M, Tsujikawa T, Andoh A. Prototype single-balloon enteroscopy with passive bending and high force transmission improves depth of insertion in the small intestine. Intest Res 2020;18:229-37. [PMID: 32252502 DOI: 10.5217/ir.2019.09150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
177 Hudesman DP, Chakravarty SD, Emond B, Ellis LA, Lefebvre P, Sadik K, Scher JU. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study. BMC Rheumatol 2020;4:16. [PMID: 32266326 DOI: 10.1186/s41927-020-0115-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
178 Yanai S, Toya Y, Nakamura S, Matsumoto T. Patients’ Preference of Topical Therapy for Ulcerative Colitis in Japan: A Web-based 3T Survey. Crohn's & Colitis 360 2020;2. [DOI: 10.1093/crocol/otaa030] [Reference Citation Analysis]
179 Takatsu N, Hisabe T, Higashi D, Ueki T, Matsui T. Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy. Core Evid 2020;15:7-20. [PMID: 32280316 DOI: 10.2147/CE.S179053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
180 Uda A, Eto Y, Li Y, Matsuda H, Demiya S, Watanabe T, Ota M, Iwakiri R, Igarashi A. Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling. Crohn's & Colitis 360 2020;2. [DOI: 10.1093/crocol/otaa017] [Reference Citation Analysis]
181 Uda A, Kuwabara H, Shimizu S, Iwakiri R, Fushimi K. Optimal use of biologics with endoscopic balloon dilatation for repeated intestinal strictures in Crohn's disease. JGH Open 2020;4:532-40. [PMID: 32514466 DOI: 10.1002/jgh3.12329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
182 Ibáñez Vodnizza SE, De La Fuente MPP, Parra Cancino EC. Approach to the Patient with Axial Spondyloarthritis and Suspected Inflammatory Bowel Disease. Rheum Dis Clin North Am 2020;46:275-86. [PMID: 32340701 DOI: 10.1016/j.rdc.2020.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
183 Zhang X, Deng QH, Deng JH, Wang SJ, Chen Q. Lovastatin derivative dehydrolovastatin ameliorates ulcerative colitis in mice by suppressing NF-κB and inflammatory cytokine expression. Korean J Physiol Pharmacol 2020;24:137-47. [PMID: 32140037 DOI: 10.4196/kjpp.2020.24.2.137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Rodríguez C, Romero E, Garrido-Sanchez L, Alcaín-Martínez G, Andrade RJ, Taminiau B, Daube G, García-Fuentes E. MICROBIOTA INSIGHTS IN CLOSTRIDIUM DIFFICILE INFECTION AND INFLAMMATORY BOWEL DISEASE. Gut Microbes 2020;12:1725220. [PMID: 32129694 DOI: 10.1080/19490976.2020.1725220] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
185 Sanderson J, Irving P. Ulcerative colitis. Oxford Textbook of Medicine 2020. [DOI: 10.1093/med/9780198746690.003.0307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 E Penna FGC, Rosa RM, da Cunha PFS, de Souza SCS, de Abreu Ferrari ML. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. BMC Gastroenterol. 2020;20:35. [PMID: 32054445 DOI: 10.1186/s12876-020-1183-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
187 Takaki Y, Mizuochi T, Eda K, Ishihara J, Yamashita Y. Laboratory values in Japanese children with newly diagnosed inflammatory bowel disease. Pediatr Int 2019;61:720-5. [PMID: 31102555 DOI: 10.1111/ped.13892] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
188 Murugesu K, Sivadasan P, Arvind M, Wei Xin W. Perforated Toxic Megacolon: The Dreaded Complication in IBD. World J Colorectal Surg 2020;9:70. [DOI: 10.4103/1941-8213.305993] [Reference Citation Analysis]
189 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Obara Y, Komatsu M, Tozawa H. High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. Perm J 2020;24:1-10. [PMID: 33482946 DOI: 10.7812/TPP/19.166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
190 Tamizifar B, Arab A. Effects of comprehensive dietary advice on the physical and mental health of patients with ulcerative colitis during the remission phase: a parallel randomized controlled clinical trial. International Journal of Food Properties 2020;23:1834-1844. [DOI: 10.1080/10942912.2020.1833034] [Reference Citation Analysis]
191 Schreiner P, Martinho-grueber M, Studerus D, Vavricka S, Tilg H, Biedermann L, für das Swiss IBDnet, eine offizielle Arbeitsgruppe der Schweiz. Gesellschaft f. Gastroenterologie. Ernährung bei entzündlichen Darmerkrankungen. Kompass Autoimmun 2020;2:96-103. [DOI: 10.1159/000509482] [Reference Citation Analysis]
192 Moroi R, Shiga H, Endo K, Yamamoto K, Kuroha M, Kanazawa Y, Kakuta Y, Kinouchi Y, Masamune A. Long-Term Prognosis of Japanese Patients with Crohn's Disease Treated by Switching Anti-Tumor Necrosis Factor-α Antibodies. Inflamm Intest Dis 2020;5:11-9. [PMID: 32232050 DOI: 10.1159/000504803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
193 Hibi T, Naganuma M, Oda E, Yamada Y, Chujoh Y, Yoshihara R, Watanabe M. Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials. Intest Res 2020;18:56-68. [PMID: 31813214 DOI: 10.5217/ir.2019.00064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
194 Tanaka S, Nemoto Y, Takei Y, Morikawa R, Oshima S, Nagaishi T, Okamoto R, Tsuchiya K, Nakamura T, Stutte S, Watanabe M. High-fat diet-derived free fatty acids impair the intestinal immune system and increase sensitivity to intestinal epithelial damage. Biochem Biophys Res Commun. 2020;522:971-977. [PMID: 31810607 DOI: 10.1016/j.bbrc.2019.11.158] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 14.3] [Reference Citation Analysis]
195 Sato R, Nagai H, Matsui H, Hebisawa A. The Author's Reply: Cooperation Among Gastroenterological, Pathological and Microbiological Departments Is Needed to Avoid the Misdiagnosis of Intestinal Tuberculosis as Inflammatory Bowel Disease. Intern Med 2019;58:3503. [PMID: 31327850 DOI: 10.2169/internalmedicine.3479-19] [Reference Citation Analysis]
196 Takenaka K, Tominaga K, Kanazawa M, Fukushi K, Tanaka T, Kanamori A, Sugaya T, Tsuchida K, Iijima M, Goda K, Irisawa A. Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. Sci Rep 2019;9:17751. [PMID: 31780764 DOI: 10.1038/s41598-019-54369-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
197 Suzuki Y, Watanabe M, Matsui T, Motoya S, Hisamatsu T, Yuasa H, Tabira J, Isogawa N, Tsuchiwata S, Arai S, Hibi T. Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis. Inflamm Intest Dis 2019;4:131-43. [PMID: 31768386 DOI: 10.1159/000502144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
198 Ishikawa K, Takesue Y, Ichiki K, Tsuchida T, Nakajima K, Ueda T, Yamada K, Takahashi Y. Risk Factors for Central Line Associated Bloodstream Infection in Patients with Inflammatory Bowel Disease. Nihon Kankyou Kansen Gakkaishi 2019;34:296-301. [DOI: 10.4058/jsei.34.296] [Reference Citation Analysis]
199 Motoya S, Tanaka H, Shibuya T, Osada T, Yamamoto T, Hongo H, Mizuno C, Saito D, Aoyama N, Kobayashi T, Ito H, Tanida S, Nojima M, Kokuma S, Hosoi E. Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study. BMC Gastroenterol. 2019;19:196. [PMID: 31752695 DOI: 10.1186/s12876-019-1110-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
200 Hiyama S, Iijima H, Sakakibara Y, Yamada T, Mukai A, Otake Y, Yamaguchi T, Araki M, Kawai S, Tsujii Y, Inoue T, Hayashi Y, Shinzaki S, Takehara T. Endoscopic alterations in Peyer's patches in patients with ulcerative colitis: A prospective, multicenter study. J Gastroenterol Hepatol 2020;35:1143-9. [PMID: 31734952 DOI: 10.1111/jgh.14933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
201 He Y, Li X, Yu H, Ge Y, Liu Y, Qin X, Jiang M, Wang X. The Functional Role of Fecal Microbiota Transplantation on Dextran Sulfate Sodium-Induced Colitis in Mice. Front Cell Infect Microbiol 2019;9:393. [PMID: 31803633 DOI: 10.3389/fcimb.2019.00393] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
202 Wu M, Li P, An Y, Ren J, Yan D, Cui J, Li D, Li M, Wang M, Zhong G. Phloretin ameliorates dextran sulfate sodium-induced ulcerative colitis in mice by regulating the gut microbiota. Pharmacol Res 2019;150:104489. [PMID: 31689519 DOI: 10.1016/j.phrs.2019.104489] [Cited by in Crossref: 85] [Cited by in F6Publishing: 71] [Article Influence: 28.3] [Reference Citation Analysis]
203 Pellicano C, Leodori G, Innocenti GP, Gigante A, Rosato E. Microbiome, Autoimmune Diseases and HIV Infection: Friends or Foes? Nutrients 2019;11:E2629. [PMID: 31684052 DOI: 10.3390/nu11112629] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
204 Sun Y, Li L, Xie R, Wang B, Jiang K, Cao H. Stress Triggers Flare of Inflammatory Bowel Disease in Children and Adults. Front Pediatr 2019;7:432. [PMID: 31709203 DOI: 10.3389/fped.2019.00432] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 17.7] [Reference Citation Analysis]
205 Hirai F, Takeda T, Takada Y, Kishi M, Beppu T, Takatsu N, Miyaoka M, Hisabe T, Yao K, Ueki T. Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis. J Gastroenterol 2020;55:133-41. [PMID: 31641874 DOI: 10.1007/s00535-019-01634-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
206 Liu J, Andrews JM, Sammour T, Bryant RV, Grafton R, Simpson E, Putrus E, Nixon C. Benefits of Exclusive Enteral Nutrition in Adults With Complex Active Crohn’s Disease: A Case Series of 13 Consecutive Patients. Crohn's & Colitis 360 2019;1. [DOI: 10.1093/crocol/otz044] [Reference Citation Analysis]
207 Głąbska D, Guzek D, Lech G. Analysis of the Nutrients and Food Products Intake of Polish Males with Ulcerative Colitis in Remission. Nutrients 2019;11:E2333. [PMID: 31581564 DOI: 10.3390/nu11102333] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
208 Li XX, Liu Y, Luo J, Huang ZD, Zhang C, Fu Y. Vitamin D deficiency associated with Crohn's disease and ulcerative colitis: a meta-analysis of 55 observational studies. J Transl Med 2019;17:323. [PMID: 31547829 DOI: 10.1186/s12967-019-2070-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
209 Yamazaki H, Matsuoka K, Fernandez J, Hibi T, Watanabe M, Hisamatsu T, Fukuhara S. Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network). BMJ Open 2019;9:e030134. [PMID: 31501121 DOI: 10.1136/bmjopen-2019-030134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
210 Kobayashi T, Udagawa E, Uda A, Hibi T, Hisamatsu T. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. J Gastroenterol Hepatol 2020;35:225-32. [PMID: 31397010 DOI: 10.1111/jgh.14825] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
211 Noguchi K, Nakai Y, Mizuno S, Isayama H, Hirano K, Kanai S, Nakamura T, Uchino R, Takahara N, Kogure H, Tada M, Koike K. Insulin secretion improvement during steroid therapy for autoimmune pancreatitis according to the onset of diabetes mellitus. J Gastroenterol 2020;55:198-204. [PMID: 31471733 DOI: 10.1007/s00535-019-01615-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
212 Matsuno Y, Hirano A, Torisu T, Okamoto Y, Fuyuno Y, Fujioka S, Umeno J, Moriyama T, Nagai S, Hori Y, Fujiwara M, Kitazono T, Esaki M. Short-term and long-term outcomes of indigo naturalis treatment for inflammatory bowel disease. J Gastroenterol Hepatol 2020;35:412-7. [PMID: 31389626 DOI: 10.1111/jgh.14823] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
213 Naganuma M, Hirai F, Kobayashi K, Watanabe K, Takeuchi K, Aoyama N, Nozawa H, Motoya S, Ohmori T, Harada A, Nagai Y, Abe T, Yamada Y, Inagaki K, Shimizu N, Kanai T, Watanabe M; ESCORT study Group. Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam. PLoS One 2019;14:e0220413. [PMID: 31381615 DOI: 10.1371/journal.pone.0220413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
214 Andoh A, Inoue R, Kawada Y, Morishima S, Inatomi O, Ohno M, Bamba S, Nishida A, Kawahara M, Naito Y. Elemental diet induces alterations of the gut microbial community in mice. J Clin Biochem Nutr 2019;65:118-24. [PMID: 31592206 DOI: 10.3164/jcbn.19-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
215 Murakami Y, Nishiwaki Y, Oba MS, Asakura K, Ohfuji S, Fukushima W, Suzuki Y, Nakamura Y. Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol 2019;54:1070-7. [PMID: 31309327 DOI: 10.1007/s00535-019-01603-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 17.3] [Reference Citation Analysis]
216 Kimura K, Yoshida A, Katagiri F, Takayanagi R, Yamada Y. Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling. Biopharm Drug Dispos 2019;40:250-61. [PMID: 31256430 DOI: 10.1002/bdd.2198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
217 Gompertz M, Sedano R. Manifestaciones clínicas y endoscópicas en enfermedad inflamatoria intestinal. Revista Médica Clínica Las Condes 2019;30:273-282. [DOI: 10.1016/j.rmclc.2019.06.002] [Reference Citation Analysis]
218 Horigome R, Sato H, Honma T, Terai S. Septicemic listeriosis during adalimumab- and golimumab-based treatment for ulcerative colitis: case presentation and literature review. Clin J Gastroenterol 2020;13:22-5. [DOI: 10.1007/s12328-019-01005-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
219 Kondo K, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Ito K, Suzuki Y, Hirota Y; Japanese Case-Control Study Group for Crohn's disease. The association between environmental factors and the development of Crohn's disease with focusing on passive smoking: A multicenter case-control study in Japan. PLoS One. 2019;14:e0216429. [PMID: 31173593 DOI: 10.1371/journal.pone.0216429] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
220 Heshmati K, Lo T, Tavakkoli A, Sheu E. Short-Term Outcomes of Inflammatory Bowel Disease after Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. Journal of the American College of Surgeons 2019;228:893-901.e1. [DOI: 10.1016/j.jamcollsurg.2019.01.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
221 Jang EJ, Ha JE, Im SG, Kim MG, Sohn HS. A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease. Clin Drug Investig 2019;39:625-30. [DOI: 10.1007/s40261-019-00784-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
222 Zhou J, Wu LY, Chen L, Guo YJ, Sun Y, Li T, Zhao JM, Bao CH, Wu HG, Shi Y. Herbs-partitioned moxibustion alleviates aberrant intestinal epithelial cell apoptosis by upregulating A20 expression in a mouse model of Crohn’s disease. World J Gastroenterol 2019; 25(17): 2071-2085 [PMID: 31114134 DOI: 10.3748/wjg.v25.i17.2071] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
223 Hisamatsu T, Kato S, Kunisaki R, Matsuura M, Nagahori M, Motoya S, Esaki M, Fukata N, Inoue S, Sugaya T, Sakuraba H, Hirai F, Watanabe K, Kanai T, Naganuma M, Nakase H, Suzuki Y, Watanabe M, Hibi T, Nojima M, Matsumoto T; DIAMOND2 Study Group. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). J Gastroenterol 2019;54:860-70. [PMID: 31041545 DOI: 10.1007/s00535-019-01582-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
224 Xu Y, Sharma A, Chen Y, Zhou H. What We Can Learn from Current Inflammatory Bowel Disease (IBD) Biological Therapy—Dose Regimen and Others. Curr Pharmacol Rep 2019;5:115-30. [DOI: 10.1007/s40495-019-00180-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
225 Higashiyama M, Sugita A, Koganei K, Wanatabe K, Yokoyama Y, Uchino M, Nagahori M, Naganuma M, Bamba S, Kato S, Takeuchi K, Omori T, Takagi T, Matsumoto S, Nagasaka M, Sagami S, Kitamura K, Katsurada T, Sugimoto K, Takatsu N, Saruta M, Sakurai T, Watanabe K, Nakamura S, Suzuki Y, Hokari R. Management of elderly ulcerative colitis in Japan. J Gastroenterol 2019;54:571-86. [PMID: 31025187 DOI: 10.1007/s00535-019-01580-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
226 Kawachi H. Histopathological diagnosis of ulcerative colitis‐associated neoplasia. Digestive Endoscopy 2019;31:31-5. [DOI: 10.1111/den.13387] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
227 Iida T, Nojima M, Nakase H. Therapeutic Efficacy and Adverse Events of Tacrolimus in Patients with Crohn's Disease: Systematic Review and Meta-Analysis. Dig Dis Sci 2019;64:2945-54. [PMID: 30982208 DOI: 10.1007/s10620-019-05619-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
228 He Y, Yu H, Ge Y, Li X, Jiang M, Liu Y, Li X, Wang Y, Guo M, Qin X, Wang X. Bacterial β-glucuronidase alleviates dextran sulfate sodium-induced colitis in mice: A possible crucial new diagnostic and therapeutic target for inflammatory bowel disease. Biochem Biophys Res Commun 2019;513:426-33. [PMID: 30967260 DOI: 10.1016/j.bbrc.2019.03.196] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
229 Hissong E, Chen Z, Yantiss RK. Cytomegalovirus reactivation in inflammatory bowel disease: an uncommon occurrence related to corticosteroid dependence. Mod Pathol 2019;32:1210-6. [DOI: 10.1038/s41379-019-0258-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
230 Kanazawa M, Takahashi F, Tominaga K, Abe K, Izawa N, Fukushi K, Nagashima K, Kanamori A, Takenaka K, Sugaya T, Iijima M, Takada A, Imai Y, Hiraishi H, Irisawa A. Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. Endosc Int Open 2019;7:E568-75. [PMID: 30957007 DOI: 10.1055/a-0869-7619] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
231 Colonetti K, Bento Dos Santos B, Nalin T, Moura de Souza CF, Triplett EW, Dobbler PT, Schwartz IVD, Roesch LFW. Hepatic glycogen storage diseases are associated to microbial dysbiosis. PLoS One 2019;14:e0214582. [PMID: 30939160 DOI: 10.1371/journal.pone.0214582] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
232 Nishida A, Imaeda H, Inatomi O, Bamba S, Sugimoto M, Andoh A. The efficacy of fecal microbiota transplantation for patients with chronic pouchitis: A case series. Clin Case Rep 2019;7:782-8. [PMID: 30997086 DOI: 10.1002/ccr3.2096] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
233 Sarbu MI, Sarbu N. Musculoskeletal Clinical and Imaging Manifestations in Inflammatory Bowel Diseases. Open Med (Wars) 2019;14:75-84. [PMID: 30847394 DOI: 10.1515/med-2019-0011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
234 Meurer MC, Mees M, Mariano LNB, Boeing T, Somensi LB, Mariott M, da Silva RCMVAF, Dos Santos AC, Longo B, Santos França TC, Klein-Júnior LC, de Souza P, de Andrade SF, da Silva LM. Hydroalcoholic extract of Tagetes erecta L. flowers, rich in the carotenoid lutein, attenuates inflammatory cytokine secretion and improves the oxidative stress in an animal model of ulcerative colitis. Nutr Res 2019;66:95-106. [PMID: 30979660 DOI: 10.1016/j.nutres.2019.03.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
235 Maehata Y, Nagata Y, Moriyama T, Matsuno Y, Hirano A, Umeno J, Torisu T, Manabe T, Kitazono T, Esaki M. Risk of surgery in patients with stricturing type of Crohn's disease at the initial diagnosis: a single center experience. Intest Res 2019;17:357-64. [PMID: 30781932 DOI: 10.5217/ir.2018.00107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
236 Tominaga K, Tsuchiya A, Sato H, Kimura A, Oda C, Hosaka K, Kawata Y, Kimura N, Hayashi K, Yokoyama J, Terai S. Co-existent ulcerative colitis and Guillain-Barré syndrome: a case report and literature review. Clin J Gastroenterol 2019;12:243-6. [PMID: 30778832 DOI: 10.1007/s12328-019-00939-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
237 Hibi T, Motoya S, Ashida T, Sai S, Sameshima Y, Nakamura S, Maemoto A, Nii M, Sullivan BA, Gasser RA Jr, Suzuki Y. Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intest Res 2019;17:375-86. [PMID: 30739435 DOI: 10.5217/ir.2018.00141] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
238 Hisamatsu T, Matsumoto T, Watanabe K, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, Andoh A, Ashida T, Endo K, Endo Y, Esaki M, Fujita H, Fujiya M, Haruma K, Hibi T, Hiraoka S, Hirata I, Hisamatsu T, Honda Y, Iijima H, Iizuka B, Ikeya K, Inoue T, Inoue S, Ishida T, Ishiguro Y, Ishihara S, Ito H, Iwakiri R, Kagaya T, Kanai T, Kashida H, Kato S, Kato J, Katsurada T, Kinjyo F, Kobayashi K, Kodama M, Kunisaki R, Kurahara K, Kurokami T, Kyouwon L, Matsuda K, Matsueda K, Matsui T, Matsumoto T, Mitsuyama K, Mizokami Y, Motoya S, Naito Y, Nakagawa T, Nakamura S, Nakase H, Nojima M, Nomura M, Ogawa A, Okazaki K, Otsuka K, Sakuraba H, Saruta M, Sasaki M, Shirai T, Suga T, Sugimura K, Sugiyama T, Suzuki Y, Takeshima F, Tamaki H, Tanaka S, Tanida S, Tominaga K, Tomizawa T, Watanabe K, Watanabe M, Watanabe K, Yamamoto S, Yamashita M, Yoshida A, Yoshimura N; DIAMOND study group. Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn’s Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]. Journal of Crohn's and Colitis 2019;13:1097-104. [DOI: 10.1093/ecco-jcc/jjz030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
239 Hata K, Anzai H, Ikeuchi H, Futami K, Fukushima K, Sugita A, Uchino M, Higashi D, Itabashi M, Watanabe K, Koganei K, Araki T, Kimura H, Mizushima T, Ueda T, Ishihara S, Suzuki Y; on behalf of the Research Group for Intractable Inflammatory Bowel Disease of the Ministry of Health, Labour and Welfare of Japan (RGIBD). Surveillance Colonoscopy for Ulcerative Colitis-Associated Colorectal Cancer Offers Better Overall Survival in Real-World Surgically Resected Cases. Am J Gastroenterol 2019;114:483-9. [DOI: 10.14309/ajg.0000000000000117] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
240 Okabayashi S, Kobayashi T, Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T. Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. Intest Res 2019;17:218-26. [PMID: 30704156 DOI: 10.5217/ir.2018.00117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
241 Pei LY, Ke YS, Zhao HH, Wang L, Jia C, Liu WZ, Fu QH, Shi MN, Cui J, Li SC. Role of colonic microbiota in the pathogenesis of ulcerative colitis. BMC Gastroenterol. 2019;19:10. [PMID: 30642266 DOI: 10.1186/s12876-019-0930-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
242 Kumagai H, Yamada K, Nakai K, Kitamura T, Mohri K, Ukawa M, Tomono T, Eguchi T, Yoshizaki T, Fukuchi T, Yoshino T, Matsuura M, Tobita E, Pham W, Nakase H, Sakuma S. Tumor recognition of peanut agglutinin-immobilized fluorescent nanospheres in biopsied human tissues. Eur J Pharm Biopharm 2019;136:29-37. [PMID: 30639308 DOI: 10.1016/j.ejpb.2019.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
243 El-Akabawy G, El-Sherif NM. Zeaxanthin exerts protective effects on acetic acid-induced colitis in rats via modulation of pro-inflammatory cytokines and oxidative stress. Biomed Pharmacother 2019;111:841-51. [PMID: 30616083 DOI: 10.1016/j.biopha.2019.01.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
244 Lin E, Katz S. Colorectal Cancer Risk and Screening in Geriatric Patients. Cancer Screening in Inflammatory Bowel Disease 2019. [DOI: 10.1007/978-3-030-15301-4_11] [Reference Citation Analysis]
245 Yanagisawa T, Mizukami H, Akiyama H, Hasegawa Y. Recurrent Cerebral Hemorrhage Associated with Ulcerative Colitis. J St Marianna Univ 2019;10:115-121. [DOI: 10.17264/stmarieng.10.115] [Reference Citation Analysis]
246 Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Sands BE. Response to Chamberlin and Borody. Am J Gastroenterol 2019;114:171-174. [DOI: 10.14309/ajg.0000000000000077] [Reference Citation Analysis]
247 Antonelli E, Villanacci V, Bassotti G. Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World J Gastroenterol 2018; 24(47): 5322-5330 [PMID: 30598577 DOI: 10.3748/wjg.v24.i47.5322] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
248 Gombert M, Carrasco-Luna J, Pin-Arboledas G, Codoñer-Franch P. The connection of circadian rhythm to inflammatory bowel disease. Transl Res 2019;206:107-18. [PMID: 30615844 DOI: 10.1016/j.trsl.2018.12.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
249 Leoncini G, Villanacci V, Marin MG, Crisafulli V, Cadei M, Antonelli E, Leoci C, Bassotti G. Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy. Tech Coloproctol. 2018;22:941-946. [PMID: 30535522 DOI: 10.1007/s10151-018-1896-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
250 Satta R, Pes GM, Rocchi C, Pes MC, Dore MP. Is probiotic use beneficial for skin lesions in patients with inflammatory bowel disease? J Dermatolog Treat 2019;30:612-6. [PMID: 30244616 DOI: 10.1080/09546634.2018.1527998] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
251 Saito S, Nakazawa K, Suzuki K, Ishikawa T, Akazawa K. Paradigm Shift of Healthcare Cost for Patients with Inflammatory Bowel Diseases: A Claims Data-Based Analysis in Japan. GastrointestDisord 2018;1:120-8. [DOI: 10.3390/gidisord1010009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
252 Delmonico T, Stephen AH, Heffernan DS. A Case of Severe Lumbar Necrotizing Soft Tissue Infection from an Ileal Pouch Fistula. Surg Infect (Larchmt) 2018;19:548-50. [PMID: 29957139 DOI: 10.1089/sur.2018.104] [Reference Citation Analysis]
253 Okabayashi S, Kobayashi T, Hibi T. Drug Lag for Inflammatory Bowel Disease Treatments in the East and West. Inflamm Intest Dis 2018;3:25-31. [PMID: 30505839 DOI: 10.1159/000491878] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
254 Furthner E, Cordonnier N, Le Dudal M, Fontbonne A, Freiche V. Is electroejaculation a safe procedure in cats? An endoscopic and histological prospective blinded study. Theriogenology 2018;119:69-75. [DOI: 10.1016/j.theriogenology.2018.06.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
255 Esaki M, Matsumoto T, Ohmiya N, Washio E, Morishita T, Sakamoto K, Abe H, Yamamoto S, Kinjo T, Togashi K, Watanabe K, Hirai F, Nakamura M, Nouda S, Ashizuka S, Omori T, Kochi S, Yanai S, Fuyuno Y, Hirano A, Umeno J, Kitazono T, Kinjo F, Watanabe M, Matsui T, Suzuki Y. Capsule endoscopy findings for the diagnosis of Crohn's disease: a nationwide case-control study. J Gastroenterol. 2019;54:249-260. [PMID: 30219994 DOI: 10.1007/s00535-018-1507-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
256 Fernández A, Simian D, Quera R, Flores L, Ibáñez P, Lubascher J, Figueroa C, Kronberg U, Pizarro G, Fluxá D. Complementary and alternative medicine in patients with inflammatory bowel disease: A survey performed in a tertiary center in Chile. Complement Ther Med 2018;40:77-82. [PMID: 30219473 DOI: 10.1016/j.ctim.2018.07.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
257 Hatton GB, Madla CM, Rabbie SC, Basit AW. All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance. Int J Pharm 2018;548:408-22. [PMID: 29969711 DOI: 10.1016/j.ijpharm.2018.06.054] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
258 Kakuta Y, Kawai Y, Okamoto D, Takagawa T, Ikeya K, Sakuraba H, Nishida A, Nakagawa S, Miura M, Toyonaga T, Onodera K, Shinozaki M, Ishiguro Y, Mizuno S, Takahara M, Yanai S, Hokari R, Nakagawa T, Araki H, Motoya S, Naito T, Moroi R, Shiga H, Endo K, Kobayashi T, Naganuma M, Hiraoka S, Matsumoto T, Nakamura S, Nakase H, Hisamatsu T, Sasaki M, Hanai H, Andoh A, Nagasaki M, Kinouchi Y, Shimosegawa T, Masamune A, Suzuki Y; MENDEL study group. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol. 2018;53:1065-1078. [PMID: 29923122 DOI: 10.1007/s00535-018-1486-7] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 14.5] [Reference Citation Analysis]
259 Kimura K, Yoshida A, Takayanagi R, Yamada Y. Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's disease: PK/PD model of ADA administered for CD. Biopharm Drug Dispos 2018;39:283-8. [DOI: 10.1002/bdd.2134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]